# Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors

> **NCT06358703** · — · NOT_YET_RECRUITING · sponsor: **US Thrombotic Microangiopathy Alliance** · enrollment: 116 (estimated)

## Conditions studied

- Immune Thrombotic Thrombocytopenia

## Interventions

- **DRUG:** Caplacizumab

## Key facts

- **NCT ID:** NCT06358703
- **Lead sponsor:** US Thrombotic Microangiopathy Alliance
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2027-05
- **Final completion:** 2028-05
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06358703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06358703, "Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06358703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*